Mankind Pharma partners with Lepra Society to establish CDCC Centres; Aims to screen 80,000 individuals

New Delhi, February 14, 2024: Mankind Pharma has announced a strategic partnership with the Lepra Society to launch an initiative aimed at eradicating, raising awareness, and treating leprosy. Under its CSR arm, the company working in the regions affected by leprosy and has established as many as five care centres across different locations.

The Comprehensive Disability Care Centers (CDCCs) are strategically positioned in regions identified as high-impact areas, including the NTR District in Andhra Pradesh, Guru Gobind Hospital in Delhi, the Government Hospital in Chandarpur, Maharashtra, the Community Care Centre in Odisha, Koraput, and Nirmal District in Telangana. These centres are operational throughout the year, addressing various issues related to leprosy and elephantiasis. The company aims to provide essential treatment and raise awareness through these centres, collaborating closely with the Lepra Society.

Sheetal Arora, CEO, Mankind Pharma, said the partnership with the Lepra Society is a step forward to eradicate leprosy. "At Mankind Pharma, we are deeply committed to the well-being of communities in India. Our partnership with the Lepra Society is a step forward in our mission to eradicate leprosy and create awareness. The CDCCs in key regions will play a crucial role in providing treatment and support to those affected by leprosy. We hope that the targeted communities will benefit from this renewed focus on leprosy," he said.

Connect with 300+ corporates, foundations and social enterprise leaders.

Nomination Deadline Countdown

00Days

:

00Hrs

:

00Mins

:

00Secs

Explore Partnerships

Mankind Pharma will undertake a range of vital activities to combat leprosy and its socio-economic impacts. Over 80,000 individuals will undergo comprehensive screening, accompanied by extensive awareness programs designed to educate and inform communities.

Additionally, the initiative aims to provide treatment to more than 6,000 patients through the morbidity management and disability program, showcasing the commitment to holistic care. Over 10 reconstructive surgeries are slated to take place, aimed at restoring normalcy for affected individuals. Recognizing the broader impact of leprosy, the initiative will also extend socio-economic support to over 400 families, addressing the multi-faceted challenges faced by communities.